Scanning and combinatorial library services – Save 20% with code TRY-BXPLIB-20

Antibody drug discovery

High specificity without the guesswork

Antibody drug discovery

Biologic discovery of novel therapeutics is one of the most important and popular areas of research, improving medical advances through engineering of antibodies or other proteins for cancer treatment, infectious diseases, and inflammatory or autoimmune disorders. Monoclonal antibodies, antibody-drug conjugates, and single-domain antibody variants have become invaluable for their robust recognition and downstream regulation of human immunologic processes.

Using antibodies to recognize cancer-related antigens and stimulate an immune attack has become increasingly important in current and future cancer treatments. Likewise, neutralizing antibodies for autoimmune and inflammatory diseases bind to and prevent pro-inflammatory factors from exacerbating the immune response. The rise of synthetic biology has removed much of the guesswork, transforming the drug discovery process from serendipity into rational design for identifying and producing safer, more effective therapies with less chance of late-stage failures in clinical trials.

Antibody Drug Discovery

Increase specificity and shorten timelines

With all drug discovery systems, the challenges are always the time and resources required to build new biological drug candidates — such as human monoclonal antibodies — and to get the highest specificity and safest drug delivery possible. With the introduction of high-throughput gene synthesis on the BioXp™ system, antigen-binding sequences can be custom-designed for increased specificity, and mutant libraries can be constructed with unprecedented speeds at competitive prices.

Express faster and with higher yields

Multi-fragment assembly cloning is ideal for creating up to 16 scFv variants overnight. And with Vmax™ X2 cells, powered by Gibson Assembly® technology, expression of single-domain antibodies are expressed faster, with higher yields in a simpler workflow, negating the need for E. coli protein expression strains.

Learn more

Improvements in target validation rates by automating and streamlining antibody production

Case study: Adopting the BioXp™ system compresses design-build-test cycle times and increases pipeline by 25% for one biopharmaceutical company developing an antibody-based therapeutic

Engineered T cells have been used successfully to treat several leukemias and solid tumors. However, building and screening engineered T cell receptors is time-consuming and labor-intensive. Learn how a biopharmaceutical company transitioned from a traditional method of building expression constructs for chimeric antigen receptors (CAR) to an automated method using the BioXp™ system. The BioXp™ system is the world’s first and only commercially available push-button automated platform for on-demand synthesis of DNA fragments, libraries, and more. The traditional method relied on manual processes for DNA fragment synthesis, cloning, and tracking the reactions. The large number of candidates required for screening made this method prone to human error, cumbersome, and complicated. Adopting the BioXp™ system streamlined the building of expression constructs, eliminating several manual processes from the workflow, and accelerated the identification of lead candidates.


Questions? Suggestions? Need additional info?

The expertise of our scientists, engineers, and supporting teams is always available. Or call us: 858.228.4115

By clicking Submit, you agree that Codex DNA may use this information to contact you about our programs, products, or services. You may opt out at any time.

Your personal data is handled according to our privacy policy. In addition, if you are located within a distributor territory, you may be contacted directly by them. We never sell your data to anyone.